Cytokinetics Inc is a biopharmaceutical company based in South San Francisco, California, dedicated to the development and potential commercialization of muscle activators and inhibitors for treating serious diseases. With a focus on small molecule drug candidates, Cytokinetics is advancing a diverse portfolio, including treatments for heart failure and hypertrophic cardiomyopathy. Their leading drugs in development, such as omecamtiv mecarbil and aficamten, are in late-stage clinical trials, showcasing the company's commitment to addressing unmet medical needs in muscle function and contractility.

CYTK Articles